Vaccini - Generalità
- JAMA, 24 marzo 2022 | “Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes”
- JAMA, 24 marzo 2022 | “Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy Outcomes”
- JAMA, editoriale 24 marzo 2022 | “COVID-19 mRNA Vaccines During PregnancyNew Evidence to Help Address Vaccine Hesitancy”
- MMWR, 4 marzo 2022 | “Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022”
- BMJ, 2 marzo 2022 |“Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis”
- New England Journal of Medicine, 2 marzo 2022 | “Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant”
- JAMA, 7 febbraio 2022 | “Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection”
- The Lancet, 4 febbraio 2022 | “Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden”
- ECDC , 31 gennaio 2022 | “Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA”
- New England Journal of Medicine, 27 gennaio 2022 | “Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines”
- The Lancet infectious Diseases, 27 gennaio 2022 | “Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy”
- ECDC , 31 gennaio 2022 | “Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA”
- New England Journal of Medicine, 27 gennaio 2022 | “Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines”
- The Lancet infectious Diseases, 27 gennaio 2022 | “Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy”
- New England Journal of Medicine, 26 gennaio 2022 | “Homologous and Heterologous Covid-19 Booster Vaccinations”
- JAMA, 21 gennaio 2022 | “Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants”
- JAMA, 21 gennaio editoriale | “Booster Vaccination to Prevent COVID-19 in the Era of Omicron An Effective Part of a Layered Public Health Approach”
- ECDC, 20 gennaio 2022 | “Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update”
- New England Journal of Medicine , 12 gennaio 2022 | “Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines”
- Nature, 12 gennaio 2022 | “COVID vaccines safely protect pregnant people: the data are in”
- New England Journal of Medicine , 5 gennaio 2022 | “Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants”
- Nature, 14 dicembre 2021 | “Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection”
- The Lancet, 2 dicembre 2021 | “Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial”
- New England Journal of Medicine , 1 dicembre 2021 | “Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans”
- JAMA, 24 novembre 2021 | “COVID-19 Vaccine Makers Plan for Annual Boosters, but It’s Not Clear They’ll BeNeeded”
- New England Journal of Medicine, editoriale 1 dicembre 2021 | “Covid-19 mRNA Vaccines — Six of One, Half a Dozen of the Other”
- New England Journal of Medicine , 11 novembre 2021 | “The Future of SARS-CoV-2 Vaccination — Lessons from Influenza”
- The Lancet, 11 novembre 2021 | “Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial”
- JAMA, 5 novembre 2021 | “Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years”
- JAMA, 4 novembre 2021 | “Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity”
- New England Journal of Medicine , 1 dicembre 2021 |“Covid-19 Vaccine Effectiveness in New York State”
- JAMA, editoriale 4 novembre 2021 | “Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity”
- The Lancet infectious Diseases , 29 ottobre 2021 | “Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study”
- The Lancet infectious Diseases , editoriale 29 ottobre 2021| “What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant?”
- MMWR, 29 ottobre 2021 | “The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021”
- New England Journal of Medicine, 15 ottobre 2021 | “Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines”
- Nature, 14 ottobre 2021 | “China’s COVID vaccines have been crucial — now immunity is waning”
- The Lancet Respiratory Medicine, 29 settembre 2021 | “COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study”
- MMWR, 24 settembre 2021 | “Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021”
- New England Journal of Medicine, 22 settembre 2021 | “Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase”
- New England Journal of Medicine, 22 settembre 2021 | “Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel”
- New England Journal of Medicine, 15 settembre 2021 | “Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel”
- New England Journal of Medicine , 8 settembre 2021 | “Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings”
- JAMA, 3 settembre 2021 | “Surveillance for Adverse Events After COVID-19 mRNA Vaccination”
- New England Journal of Medicine , editoriale 8 settembre 2021 |“Covid-19 Vaccine Effectiveness and the Test-Negative Design”
- JAMA, editoriale 3 settembre 2021 | “Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink”
- JAMA, 3 settembre 2021 | “Surveillance for Adverse Events After COVID-19 mRNA Vaccination”
- New England Journal of Medicine , editoriale 8 settembre 2021 |“Covid-19 Vaccine Effectiveness and the Test-Negative Design”
- JAMA, editoriale 3 settembre 2021 | “Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink”
- MMWR, 18 agosto 2021 | “Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021”
- MMWR, 18 agosto 2021 | “Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021”
- MMWR, 30 luglio 2021 | “COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021”
- New England Journal of Medicine, 28 luglio 2021 | “Covid-19 Breakthrough Infections in Vaccinated Health Care Workers”
- JAMA Internal Medicine , 26 luglio 2021 | “Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose”
- New England Journal of Medicine, 22 luglio 2021 | “Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines”
- New England Journal of Medicine, 21 luglio 2021 | “Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant”
- New England Journal of Medicine, 8 luglio 2021 | “SARS-CoV-2 Variants and Vaccines”
- New England Journal of Medicine, 30 giugno 2021 | “Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines”
- JAMA Cardiology, 29 giugno 2021 | “Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines”
- JAMA Cardiology, 29 giugno 2021 | “Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military”
- New England Journal of Medicine, 23 giugno 2021 | “Effect of Vaccination on Household Transmission of SARS-CoV-2 in England”
- The Lancet Infectious Diseases, 23 giugno 2021 | “Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study”
- The Lancet Infectious Diseases, 23 giugno 2021 | “Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study”
- New England Journal of Medicine, 17 giugno 2021 | “Spike D614G — A Candidate Vaccine Antigen Against Covid-19”
- New England Journal of Medicine, 17 giugno 2021 | “Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons”
- AIFA, 26 maggio 2021 | “Complicanze tromboemboliche post-vaccinazione anti-COVID-19 con Vaxzevria (ChAdOx1 nCov-19, AstraZeneca) o con COVID-19 Vaccine Janssen (Ad.26. COV2.S, Johnson & Johnson)”
- JAMA, 25 maggio 2021 | “Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults”
- New England Journal of Medicine, 20 maggio 2021 | “Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents”
- MMWR, 14 maggio 2021 | “Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021”
- Istituto Superiore di Sanità, 11 maggio 2021 | “Impatto della vaccinazione COVID-19 sul rischio di infezione da SARS-CoV-2 e successivo ricovero e decesso in Italia (27.12.2020-03.05.2021)”
- MMWR, 27 aprile 2021 | “Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021”
- JAMA Internal Medicine, 27 aprile 2021 | “Association of Facial Paralysis With mRNA COVID-19 Vaccines”
- The Lancet Infectiuos Diseases, 27 aprile 2021 | “ Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study”
- The Lancet , 23 aprile 2021 | “Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study”
- The Lancet Microbe, 20 aprile 2021 | “COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room”
- New England Journal of Medicine, 21 aprile 2021 | “Vaccine Breakthrough Infections with SARS-CoV-2 Variants”
- The Lancet Infectious Disease, 13 aprile 2021 | “SARS-CoV-2 incidence and vaccine escape”
- New England Journal of Medicine, 7 aprile 2021 | “Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351”
- New England Journal of Medicine, 7 aprile 2021 | “Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)”
- MMWR, 29 marzo 2021 | “Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021”
- New England Journal of Medicine, 23 marzo 2021 | “SARS-CoV-2 Infection after Vaccination in Health Care Workers in California”
- JAMA , 17 marzo 2021 | “COVID-19 Vaccines vs Variants—Determining How Much Immunity Is Enough”
- AIFA, 15 marzo 2021 – aggiornamento | “Domande e risposte sui vaccini COVID-19”
- Science, 12 marzo 2021 | “Immunity to SARS-CoV-2 variants of concern”
- Nature, 11 marzo 2021 | “Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies”
- JAMA, 10 marzo 2021 | “CDC Interim Recommendations for Fully Vaccinated People – An Important First Step”
- New England Journal of Medicine, 10 marzo 2021 | “Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine”
- JAMA, 8 marzo 2021 | “Acute Allergic Reactions to mRNA COVID-19 Vaccines”
- New England Journal of Medicine, 3 marzo 2021 | “An Uncertain Public – Encouraging Acceptance of Covid-19 Vaccines”
- JAMA, 4 marzo 2021 | “Approaches for Optimal Use of Different COVID-19 VaccinesIssues of Viral Variants and Vaccine Efficacy”
- New England Journal of Medicine, 3 marzo 2021 | “Choices in a Crisis — Individual Preferences among SARS-CoV-2 Vaccines”
- JAMA, 1 marzo 2021 | “Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2”
- Nature, 26 febbraio 2021 | “COVID research updates: A COVID vaccine passes a real-world test with flying colours”
- JAMA, 25 febbraio 2021 | “SARS-CoV-2 Vaccines”
- The Lancet Infectius Diseases, 17 febbraio 2021 | ” What does 95% COVID-19 vaccine efficacy really mean?”
- Science, 16 febbraio 2021 | “How soon will COVID-19 vaccines return life to normal?”
- JAMA, 8 febbraio 2021 | “COVID-19 Vaccination in Pregnant and Lactating Women”
- JAMA, 8 febbraio 2021 | “Pregnancy, Postpartum Care, and COVID-19 Vaccination in 2021”
- Nature, 8 febbraio 2021 | “Variant-proof vaccines – invest now for the next pandemic”
- New England Journal of Medicine, 4 febbraio 2021 | “Vaccine Innovations – Past and Future”
- AIFA, 4 febbraio 2021 | “Primo rapporto sulla sorveglianza dei vaccini COVID-19”
- European Centre for Disease Prevention and Control, 1 febbraio 2021 | “Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA”
- Nature, 29 gennaio 2021 | “How to redesign COVID vaccines so they protect against variants”
- The Lancet, 29 gennaio 2021 | “Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial”
- The Lancet , 29 gennaio 2021 | “Next-generation COVID-19 vaccines: here come the proteins”
- Science, 29 gennaio 2021 | “Lessons in antiviral immunity”
- Annals of Internal Medicine , 5 gennaio 2021 |“Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment”
- Annals of Internal Medicine , 5 gennaio 2021 | “A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose”
- New England Journal of Medicine , 30 dicembre 2020 | “Maintaining Safety with SARS-CoV-2 Vaccines”
- MMWR, 22 dicembre 2020 | “The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020”
- Nature Reviews , 22 dicembre 2020 | “A guide to vaccinology: from basic principles to new developments”
- Annals of Internal Medicine, 24 novembre 2020 | “Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases”
- Annals of Internal Medicine, 20 novembre 2020 | “Ethical and Scientific Considerations Regarding the Early Approval and Deployment of a COVID-19 Vaccine”
- Science , 13 novembre 2020 |“Understanding COVID-19 vaccine efficacy”
- Accademia dei Lincei, 10 novembre 2020 | “Verso il vaccino: undici in fase 3. La mappa degli sforzi anti-Covid”
- Annals of Internal Medicine, 22 ottobre 2020 | “Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials”
- JAMA, 16 ottobre 2020 | “Answering Key Questions About COVID-19 Vaccines”
- JAMA, 16 ottobre 2020 | “Postlicensure Evaluation of COVID-19 Vaccines”
- Nature, 23 settembre 2020 | “SARS-CoV-2 vaccines in development”
- The Lancet, 4 settembre 2020 | “Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia“
- The Lancet, 4 settembre 2020 (editoriale) | ”COVID-19 vaccines: early success and remaining challenges”
- JAMA , 3 settembre 2020 | “COVID-19 and mRNA Vaccines—First Large Test for a New Approach”
- The Lancet, 20 luglio 2020 | “Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial“
- The Lancet, 20 luglio 2020 (editoriale) | “Encouraging results from phase 1/2 COVID-19 vaccine trials”
- JAMA, 6 luglio 2020 | “The Development of COVID-19 VaccinesSafeguards Needed“
- New England Journal of Medicine, 1 luglio 2020 | “Accelerating Development of SARS-CoV-2 Vaccines — The Role for Controlled Human Infection Models“
- New England Journal of Medicine, 18 giugno 2020 | “Amplifying RNA Vaccine Development”
- The Lancet, 20 luglio 2020 | “Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial“
- The Lancet, 20 luglio 2020 (editoriale) | “Encouraging results from phase 1/2 COVID-19 vaccine trials”
- JAMA, 6 luglio 2020 | “The Development of COVID-19 VaccinesSafeguards Needed“
- New England Journal of Medicine, 1 luglio 2020 | “Accelerating Development of SARS-CoV-2 Vaccines — The Role for Controlled Human Infection Models“
- New England Journal of Medicine, 18 giugno 2020 | “Amplifying RNA Vaccine Development”